Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...

Grew ARR 29% year-over-year to $877 millionExpanded SaaS ARR 39% year-over-year to $540 millionFinished the year with an ~80% year-over-year ...

We recently published a list of Top 10 Stocks to Buy According to Akre Capital Management. In this article, we are going to ...

Just as artificial intelligence has helped programmers slash the time it takes to write code, hackers are also finding it’s a ...

Akre Capital Management follows a disciplined investment philosophy centered around identifying exceptional businesses ...

Charlotte-Mecklenburg Schools Superintendent Crystal Hill on Tuesday recommended a total 2025-26 budget of nearly $2.1 ...

While PE investment can accelerate growth and offer financial freedom, it may also bring cultural shifts and operational ...

City sources said on Tuesday that a deal was ... increasing value attached to software providers which boast large recurring revenues and which are at the forefront of the seismic shift towards ...

CR Land's net debt/equity ratio is low among state-owned developers at around 32%, despite its heavier emphasis on investment properties. Although the housing price contraction in 2022-24 has squeezed ...